AL AMYLOIDOSIS

This study looks at how long people with AL amyloidosis should continue taking daratumumab after their first treatment to keep the disease from coming back. About 96 adults who have already responded to initial daratumumab therapy will be randomly assigned to either a shorter or …

This study is for people newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins damage organs. It compares two treatment approaches: chemotherapy followed by a stem cell transplant versus chemotherapy alone. The goal is to see which strategy better controls t…

This study tests a drug called teclistamab in 30 people with AL amyloidosis, a rare disease where abnormal proteins damage organs. Participants have already had other treatments that didn't work well enough. The goal is to see if teclistamab can improve blood markers of the disea…

This study aims to improve initial treatment for people with systemic light chain (AL) amyloidosis who have a specific genetic change called t(11;14). All 41 participants will start with a standard drug combination (daratumumab, bortezomib, and dexamethasone). If their blood resp…

This study tests a drug called elranatamab in people with AL amyloidosis that has come back or not responded to prior treatment. The goal is to find a safe dose and see if the drug can reduce abnormal protein levels in the blood. About 49 adults will take part in this early-phase…

This study tests a drug called belantamab mafodotin in people with AL amyloidosis, a rare disease where abnormal proteins build up in organs. The goal is to find the safest and most effective dose to control the disease. About 37 participants will be enrolled, and the study has t…

This study tests whether a special PET scan using a radioactive tracer called [18F]Florbetaben can accurately diagnose cardiac AL amyloidosis, a rare condition where abnormal proteins build up in the heart. About 200 adults with suspected cardiac amyloidosis will receive one inje…

This study will screen 760 people in Italy who have early blood conditions (MGUS or smoldering multiple myeloma) to find cases of AL amyloidosis sooner. Researchers will also test new diagnostic tools and track treatment responses. The goal is to improve diagnosis and care for th…

This study aims to understand how a specific sugar modification (N-glycosylation) on abnormal proteins contributes to AL amyloidosis, a rare disease where these proteins build up and damage organs. Researchers will analyze blood and bone marrow samples from 100 adults with relate…

This study is creating a large European registry of 400 newly diagnosed AL amyloidosis patients. Researchers will collect blood and tissue samples to study the disease at a molecular level, aiming to improve diagnosis and predict outcomes. The goal is to better understand the dis…

This study looks at how a specific gene (IGLV1-44) causes two rare blood disorders: AL amyloidosis and POEMS syndrome. Researchers will analyze blood and bone marrow samples from 100 adults with these conditions or multiple myeloma. The goal is to find unique patterns in the gene…

This study is building a large registry of 5000 people with AL amyloidosis, a rare disease where abnormal proteins damage organs. Researchers will collect information from medical records and follow-ups to see how the disease progresses and how current treatments affect it. No ne…

This study is creating a biobank and data registry for people with amyloidosis, a rare disease where abnormal proteins build up in organs. Researchers will collect blood, urine, and tissue samples along with medical information from 505 participants. The goal is to store these ma…

This study is creating a large database of up to 5,000 people in Ohio with plasma cell disorders like multiple myeloma and amyloidosis. Researchers will track treatments, outcomes, and quality of life, while also offering patients access to expert consultations and information ab…